利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2659 条记录 (耗时 0.036 秒)

    COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTION
    83.
    发明公开
    COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTION 审中-公开

    公开(公告)号：US20230142090A1

    公开(公告)日：2023-05-11

    申请号：US17916368

    申请日：2021-03-31

    申请人： CORNELL UNIVERSITY

    发明人： Erick Maosa Bosire ,  Craig Altier

    IPC分类号： A61K31/201 ,  A61K35/745 ,  A61K35/747 ,  A61K47/10 ,  A61K47/20 ,  A61K47/44 ,  A61P31/04

    CPC分类号： A61K31/201 ,  A61K35/745 ,  A61K35/747 ,  A61K47/10 ,  A61K47/20 ,  A61K47/44 ,  A61P31/04 ,  C12Y503/03013 ,  A61K2035/115

    摘要： Disclosed herein is a method for inhibiting or preventing Vibrio cholera toxin production in a subject, the method comprising enterally administering to the subject a pharmaceutically effective amount of a fatty acid dissolved or suspended in a pharmaceutically acceptable carrier, wherein the fatty acid contains 10 to 30 carbon atoms, such as an unsaturated fatty acid such as a cis-2-unsaturated fatty acid, such as a fatty acid having the formula:




    wherein n is an integer of 6-26, and the fatty acid optionally includes a second carbon-carbon double bond resulting from removal of two hydrogen atoms on adjacent carbon atoms. Also disclosed herein is a method for treating or preventing a Vibrio infection comprising administering to a subject in need of treatment an effective amount of a genetically engineered bacterium, wherein the genetically engineered bacterium comprises an exogenous nucleic acid encoding an enzyme that produces a diffusible signal factor (DSF) by introducing a cis-2 double bond to a fatty acid.

    PROBIOTIC CULTURE AND USE THEREOF
    85.
    发明申请
    PROBIOTIC CULTURE AND USE THEREOF 有权

    公开(公告)号：US20230131386A1

    公开(公告)日：2023-04-27

    申请号：US17726041

    申请日：2022-04-21

    申请人： GLAC BIOTECH CO., LTD.

    发明人： Hsieh-Hsun HO ,  Ching-Wei CHEN ,  Yu-Fen HUANG ,  Tsai-Hsuan YI ,  Yi-Wei KUO ,  Jia-Hung LIN ,  Shin-Yu TSAI

    IPC分类号： A23L33/135 ,  A61K35/745 ,  A61K35/747 ,  A61P29/00 ,  A61P31/04

    摘要： Disclosed herein is a probiotic culture prepared by cultivating a probiotic mixture in a collagen solution. The probiotic mixture includes, in a number ratio of, Lactobacillus acidophilus TYCA06 deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 15210, to Lactobacillus salivarius subsp. salicinius AP-32 deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and to Bifidobacterium animalis subsp. lactis CP-9 deposited at the CCTCC under an accession number CCTCC M 2014588, which ranges from 1:0.125:0.125 to 1:8:8. Also disclosed herein is use of the probiotic culture for improving skin condition and for inhibiting pathogenic infection.

    Lactobacillus crispatus KBL693 strain and use thereof
    87.
    发明授权
    Lactobacillus crispatus KBL693 strain and use thereof 有权

    公开(公告)号：US11633439B2

    公开(公告)日：2023-04-25

    申请号：US17448620

    申请日：2021-09-23

    申请人： KoBioLabs, Inc.

    发明人： Woo Ri Ko ,  June Chul Lee ,  Tae-Wook Nam ,  Gwang Pyo Ko ,  Hyun Ju You ,  So Yon Yoon ,  Seok Cheon Song

    IPC分类号： A61K35/747 ,  A23L33/135 ,  A61P11/06 ,  A61P37/08 ,  A61P31/10 ,  A61K8/99

    摘要： A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.

    COMPOSITION FOR TREATING CLIMACTERIC DISORDER COMPRISING LACTOBACILLUS GASSERI BNR17
    88.
    发明申请
    COMPOSITION FOR TREATING CLIMACTERIC DISORDER COMPRISING LACTOBACILLUS GASSERI BNR17 有权

    公开(公告)号：US20230124145A1

    公开(公告)日：2023-04-20

    申请号：US17759872

    申请日：2021-02-17

    申请人： ACEBIOME INC.

    发明人： Han-Oh PARK ,  Myeong Hee KIM ,  Bong Jun JUNG ,  Wonbeak YOO

    IPC分类号： A61K35/747 ,  A61K36/489 ,  A61P15/12

    摘要： The present invention relates to a pharmaceutical composition for treating climacteric disorder, containing Lactobacillus gasseri BNR17 as an active ingredient, and a functional food composition for preventing or ameliorating climacteric symptoms, containing Lactobacillus gasseri BNR17 as an active ingredient. Lactobacillus gasseri BNR17 according to the present invention has an excellent effect of treating, preventing, or ameliorating various climacteric symptoms, such as amelioration of osteoporosis, which is the representative symptom of climacterium, amelioration of involutional depression, amelioration of pain hypersensitivity, and amelioration of vaginal dryness.

    Nutritional supplements and therapeutic compositions comprising probiotics
    90.
    发明授权
    Nutritional supplements and therapeutic compositions comprising probiotics 有权

    公开(公告)号：US11617772B2

    公开(公告)日：2023-04-04

    申请号：US16566150

    申请日：2019-09-10

    申请人： Direct Digital, LLC

    发明人： Natalie Jones ,  Mikala Hukka

    IPC分类号： A61K35/747 ,  A61K35/745 ,  A61K31/197 ,  A61K36/84 ,  A61K31/4045 ,  A23L33/135 ,  A23L33/175 ,  A23L33/105 ,  A61K31/20 ,  A61K47/12 ,  A61K47/02

    摘要： Disclosed herein are therapeutic compositions and nutritional supplements comprising probiotic mixtures and sleep-support ingredients, and a method of treating digestive discomfort and sleep problems comprising administering an effective amount of a therapeutic composition comprising a probiotic component and a sleep support component. According to embodiments, therapeutic compositions for improved digestion are provided comprising: a probiotic component, comprising: at least one of Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium animalis, Lactobacillus rhamnosus, and Lactobacilus paracasei; and a sleep support component, comprising: at least one of gamma-aminobutyric acid (GABA), valerian root extract, and melatonin. The therapeutic compositions are effective in treating both sleep disorders and digestive discomfort.